Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Next Previous
Search
Trial Profile

A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 08 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Zelenectide pevedotin (Primary) ; Avelumab; Carboplatin; Cisplatin; Gemcitabine
  • Indications Bladder cancer; Pelvic cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms Duravelo-2
  • Sponsors Bicycle Therapeutics

Most Recent Events

  • 01 May 2025 According to Bicycle Therapeutics media release, company will present data from this study as a poster presentation at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting.
  • 13 Jan 2025 According to Bicycle Therapeutics media release, Phase 2/3 Duravelo-2 Cohort 1 and Cohort 2 dose selection data expected in 2H 2025.
  • 12 Dec 2024 According to Bicycle Therapeutics media release, dose selection and topline data from Phase 2/3 Duravelo-2 trial planned for 2H 2025

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top